- Home
- / Pharmaspectra
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Pharmaspectra financials data including stock price, CreditSafe score, income statement, balance sheet, and acquistions and subsidiaries.
Revenue
$12.9 M
FY, 2021
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2020 | FY, 2021 |
|---|---|---|
| Revenue | 9.9M | 12.9M |
| Cost of goods sold | 1.5M | 1.6M |
| Gross profit | 8.4M | 11.2M |
| Gross profit margin, % | 85.1% | 87.3% |
| General and administrative expense | 20.8M | 18.6M |
| Operating expense total | 20.8M | 18.6M |
| EBIT | (12.4M) | (7.4M) |
| EBIT margin, % | -124.7% | -57.6% |
| Interest income | 251.0 | 308.9K |
| Interest expense | 1.7K | 33.8K |
| Pre tax profit | (20.0M) | (14.0M) |
| Income tax expense | (537.5K) | (4.3M) |
| Net Income | (19.3M) | (9.7M) |
Acquisitions & Subsidiaries
| Company name | Date | Deal size |
|---|---|---|
| Lorem | Dec 23, 2021 | $40.0M |
| Ipsum | Jan 18, 2022 | $30.0M |
| Lorem Ipsum | Feb 18, 2022 | $25.0M |
| Dolor | Oct 21, 2021 | $60.0M |
Premium Content only available in Craft’s Intelligence Portal View acquisitions and subsidiaries by company, date, and deal size. Understanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm. Learn more |